Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430073 | 0.89 | — | — | |
| SCHEMBL5425412 | 0.79 | POLQ (0.40) | POLQ | |
| SCHEMBL5422142 | 0.69 | POLQ (0.45) | POLQ | |
| SCHEMBL5419202 | 0.65 | TSPO (0.40) | — | |
| SCHEMBL5418860 | 0.64 | TSPO (0.67) | — | |
| SCHEMBL5430217 | 0.64 | HTR1A (0.45) | — | |
| SCHEMBL5424183 | 0.64 | TSPO (0.51) | — | |
| SCHEMBL5416490 | 0.64 | TSPO (0.51) | — | |
| SCHEMBL5416391 | 0.64 | TSPO (0.52) | — | |
| SCHEMBL9597694 | 0.63 | GRIN2D (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | POLQ 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.